Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial.
Sylvie LorenzenThorsten Oliver GötzePeter C Thuss-PatienceMatthias BieblNils HomannMichael SchenkUdo LindigVera HeuerAlbrecht KretzschmarEray GoekkurtGeorg Martin HaagJorge Riera-KnorrenschildClaus BollingRalf-Dieter HofheinzTianzuo ZhanStefan AngermeierThomas Jens EttrichAlexander Reinhard SiebenhünerMoustafa ElshafeiWolf Otto BechsteinTimo GaiserMaria LooseDisorn SookthaiChristina KoppClaudia PauligkSalah-Eddin Al-Batrannull nullPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Within the limitations of the exploratory nature of the data, the addition of ATZ to perioperative FLOT is safe and improved postoperative stage and histopathologic regression.
Keyphrases
- phase ii
- patients undergoing
- double blind
- open label
- clinical trial
- phase iii
- placebo controlled
- cardiac surgery
- locally advanced
- papillary thyroid
- squamous cell
- electronic health record
- study protocol
- acute kidney injury
- cross sectional
- rectal cancer
- squamous cell carcinoma
- big data
- lymph node metastasis
- machine learning
- childhood cancer
- data analysis
- radiation therapy
- deep learning